Landmark pancreatic cancer treatment paves way for targeting other tricky tumors

Landmark pancreatic cancer treatment paves way for targeting other tricky tumors

Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumors will be next

The landmark success of a drug against an ‘undruggable’ cancer is spurring fresh optimism in the quest to treat seemingly untouchable tumour targets.

The experimental drug, daraxonrasib , disarms all three members of the RAS family of proteins, which are linked to some of the deadliest cancers. Designing drugs that target the RAS proteins has been notoriously challenging . But a large clinical trial has found that daraxonrasib nearly doubled survival — from 6.7 months to 13.2 months — in people with a form of advanced pancreatic cancer.

The results were presented to a packed room at the American Society of Clinical Oncology annual meeting in Chicago, Illinois, on 31 May, and published in the New England Journal of Medicine . At the conference, the talk was met with a long standing ovation, says Ecaterina Dumbrava, an oncologist at the University of Texas MD Anderson Cancer Center in Houston. “After more than a decade without major advances in treatment for pancreatic cancer, seeing this is really emotional,” she says.

If you're enjoying this article, consider supporting our award-winning journalism by subscribing . By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.

That success is raising hopes that other challenging targets might also soon fall. Nature talked to researchers about progress in targeting RAS and other “undruggable” cancer proteins that can’t be bested with conventional approaches.

RAS proteins are molecular on–off switches that help to control cell growth and division. But some mutations leave RAS proteins stuck in the ‘on’ position, which drives tumour growth.